Oral dyskinesias and striatal lesions in rats after long-term co- treatment with haloperidol and 3-nitropropionic acid

Neuroscience

Volumn 87, Issue 3, 1998, Pages 639-648

  Andreassen, O A ^a   Ferrante, R J ^b,c   Beal, M F ^d   Jorgensen H A ^a  

^a UNIVERSITY OF BERGEN   (Norway)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Basal ganglia; Energy impairment; Neurodegeneration; Neuroleptics; Tardive dyskinesia; Vacuous chewing movements

Indexed keywords

3 NITROPROPIONIC ACID; GLUTAMIC ACID; HALOPERIDOL DECANOATE; NEUROLEPTIC AGENT; SUCCINATE DEHYDROGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BASAL GANGLION; BRAIN INJURY; CONTROLLED STUDY; CORPUS STRIATUM; DOSE RESPONSE; DRUG MIXTURE; FEMALE; INTRAMUSCULAR DRUG ADMINISTRATION; MASTICATION; NERVE DEGENERATION; NEUROTOXICITY; NONHUMAN; OROFACIAL DYSKINESIA; PRIORITY JOURNAL; RAT; SUBCUTANEOUS DRUG ADMINISTRATION; TARDIVE DYSKINESIA;

ANALYSIS OF VARIANCE; ANIMALS; ANTI-DYSKINESIA AGENTS; ANTIHYPERTENSIVE AGENTS; BEHAVIOR, ANIMAL; CORPUS STRIATUM; DYSKINESIA, DRUG-INDUCED; FEMALE; GLIAL FIBRILLARY ACIDIC PROTEIN; HALOPERIDOL; MASTICATION; MOUTH; NADPH DEHYDROGENASE; NERVE DEGENERATION; NEUROGLIA; NEURONS; NITRO COMPOUNDS; PROPIONIC ACIDS; RATS; RATS, SPRAGUE-DAWLEY; TYROSINE 3-MONOOXYGENASE;

EID: 0032483106     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-4522(98)00160-2     Document Type: Article

References (46)

1. American Psychiatric Association Task Force on Tardive Dyskinesia (1992) Tardive Dyskinesia: A Task Force Report of the American Psychiatric Association. APA Press, Washington, DC.
2. Andreassen O. A., Aamo T. O., Jørgensen H. A. Inhibition by memantine of the development of persistent oral dyskinesias induced by long-term haloperidol treatment of rats. Br. J. Pharmac. 119:1996;751-757.
3. Andreassen O. A., Finsen B., Østergaard K., Sørensen J. C., West M. J., Jørgensen H. A. Rats with haloperidol-induced oral dyskinesias have reduced number of striatal neurons expressing preproenkephalin mRNA. Soc. Neurosci. Abstr. 21:1995;470.
4. Andreassen O. A., Jørgensen H. A. GM1 ganglioside attenuates the development of vacuous chewing movements induced by long-term haloperidol treatment of rats. Psychopharmacology. 116:1994;517-522.
5. Andreassen O. A., Jørgensen H. A. The mitochondrial toxin 3-nitropropionic acid induces vacuous chewing movements in rats. Implications for tardive dyskinesia? Psychopharmacology. 119:1995;474-476.
6. Beal M. F. Aging, energy, and oxidative stress in neurodegenerative diseases. Ann. Neurol. 38:1995;357-366.
7. Behl C., Rupprecht R., Skutella T., Holsboer F. Haloperidol-induced cell death - mechanism and protection with vitamin E in vitro. NeuroReport. 7:1995;360-364.
8. Behl C., Lezoualch F., Widmann M., Rupprecht R., Holsboer F. Oxidative stress-resistant cells are protected against haloperidol toxicity. Brain Res. 717:1996;193-195.
9. Bowling A. C., Mutisya E. M., Walker L. C., Price D. L., Cork L. C., Beal M. F. Age-dependent impairment of mitochondrial function in primate brain. J. Neurochem. 60:1993;1964-1967.
10. Burkhardt C., Kelly J. P., Lim Y. H., Filley C. M., Parker W. D. Jr. Neuroleptic medications inhibit complex I of the electron transport chain. Ann. Neurol. 33:1993;512-517.
11. Byczkowski J. Z., Borysewicz R. The action of chlorpromazine and imipramine on rat brain mitochondria. Gen. Pharmac. 10:1979;369-372.
12. Cadet J. L., Kahler L. Free radical mechanisms in schizophrenia and tardive dyskinesia. Neurosci. Biobehav. Rev. 18:1994;457-467.
13. Cadet J. L., Lohr J. B., Jeste D. V. Free radicals and tardive dyskinesia. Trends Neurosci. 9:1986;107-108.
14. Clow A., Jenner P., Marsden S. D. Changes in dopamine-mediated behaviour during one year's neuroleptic treatment. Eur. J. Pharmac. 57:1979;365-375.
15. Coyle J. T., Puttfarcken P. Oxidative stress, glutamate, and neurodegenerative disorders. Science. 262:1993;689-695.
16. Crane G. E. Persistent dyskinesia. Br. J. Psychiat. 122:1973;395-405.
17. DeKeyser J. Excitotoxic mechanisms may be involved in the pathophysiology of tardive dyskinesia. Clin. Neuropharmac. 14:1991;562-565.
18. Dickson P. R., Lang C. G., Hinton S. C., Kelley A. E. Oral stereotypy induced by amphetamine microinjections into striatum: an anatomical mapping study. Neuroscience. 61:1994;81-91.
19. Donzanti B. A., Hite J. F., Yamamoto B. K. Extracellular glutamate levels increase with age in the lateral striatum: potential involvement of presynaptic D-2 receptors. Synapse. 13:1993;376-382.
20. Egan M. F., Hurd Y., Hyde T. M., Weinberger D. R., Wyatt R. J., Kleinman J. E. Alterations in mRNA levels of D2 receptors and neuropeptides in striatonigral and striatopallidal neurons of rats with neuroleptic-induced dyskinesias. Synapse. 18:1994;178-189.
21. Ferrante R. J., Kowall N. W., Cipollini P. B., Storey E., Beal M. F. Excitotoxin lesions in primates as a model for Huntington's disease: histopathologic and neurochemical characterization. Expl Neurol. 119:1993;46-71.
22. Gallagher C. H., Koch J. H., Mann D. M. The effect of phenothiazine on the metabolism of liver mitochondria. Biochem. Pharmac. 14:1965;789-797.
23. Glazer W. M., Morgenstern H., Schooler N., Berkman C. S., Moore D. C. Predictors of improvement in tardive dyskinesia following discontinuation of neuroleptic medication. Br. J. Psychiat. 157:1990;585-592.
24. Goff D. C., Tsai G., Beal M. F., Coyle J. T. Tardive dyskinesia and substrates of energy metabolism. Am. J. Psychiat. 152:1995;1730-1736.
25. Gunne L. M., Andersson U., Bondesson U., Johansson P. Spontaneous chewing movements in rats during acute and chronic antipsychotic drug administration. Pharmac. Biochem. Behav. 25:1986;897-901.
26. Jeste D. V., Caligiuri M. P. Tardive dyskinesia. Schizophr. Bull. 19:1993;303-315.
27. Jeste D. V., Lohr J. B., Manley M. Study of neuropathological changes in the striatum following 4, 8 and 12 months of treatment with fluphenazine in rats. Psychopharmacology. 106:1992;154-160.
28. Jeste D. V., Potkin S. G., Sinha S., Feder S., Wyatt R. J. Tardive dyskinesia - reversible and persistent. Archs gen. Psychiat. 36:1979;585-590.
29. Kane J. M. (1995) Tardive dyskinesia: epidemiological and clinical presentation. In Psychopharmacology: The Fourth Generation of Progress (eds Bloom F. E. and Kupfer D. J.), pp. 1485-1495. Raven, New York.
30. Lohr J. B. Oxygen radicals and neuropsychiatric illness. Archs gen. Psychiat. 48:1991;1097-1106.
31. McGeer E. G., McGeer P. L. Duplication of biochemical changes of Huntington's chorea by intrastriatal injections of glutamic and kainic acids. Nature. 263:1976;517-519.
32. Meshul C. K., Stallbaumer R. K., Taylor B., Janowsky A. Haloperidol-induced morphological changes in striatum are associated with glutamate synapses. Brain Res. 648:1994;181-195.
33. Miller R., Chouinard G. Loss of striatal cholinergic neurons as a basis for tardive dyskinesia and L-dopa-induced dyskinesias, neuroleptic-induced supersensitivity psychosis and refractory schizophrenia. Biol. Psychiat. 34:1993;713-738.
34. Mion C. C., Andreasen N. C., Arndt S., Swayze V. W., Cohen G. A. MRI abnormalities in tardive dyskinesia. Psychiat. Res. 40:1991;157-166.
35. Moghaddam B., Bunney B. S. Depolarization inactivation of dopamine neurons: terminal release characteristics. Synapse. 14:1993;195-200.
36. Price M. T., Olney J. W., Haft R. Age-related changes in glutamate concentration and synaptosomal glutamate uptake in adult rat brain. Life Sci. 28:1981;1365-1370.
37. Saji M., Reis D. J. Delayed transneuronal death of substrantia nigra neurons prevented by gamma-aminobutyric acid agonist. Science. 235:1987;66-69.
38. See R. E. Striatal dopamine metabolism increases during long-term haloperidol administration in rats but shows tolerance to acute challenge with raclopride. Neurosci. Lett. 129:1991;265-268.
39. Shigenaga M. K., Hagen T. M., Ames B. N. Oxidative damage and mitochondrial decay in aging. Proc. natn. Acad. Sci. U.S.A. 91:1994;10771-10778.
40. Shirakawa O., Tamminga C. A. Basal ganglia GABA(a) and dopamine D-1 binding site correlates of haloperidol-induced oral dyskinesias in rat. Expl Neurol. 127:1994;62-69.
41. Tamminga C. A., Dale J. M., Goodman L., Kaneda H., Kaneda N. Neuroleptic-induced vacuous chewing movements as an animal model of tardive dyskinesia: a study in three rat strains. Psychopharmacology. 102:1990;474-478.
42. Vincent S., Johansson O. Striatal neurons containing somatostatin- and avian pancreatic polypeptide-like activities and NADPH-diaphorase activity: a light and electron microscopic study. J. comp. Neurol. 217:1983;252-263.
43. Waddington J. L. Schizophrenia, affective psychoses, and other disorders treated with neuroleptic drugs: the enigma of tardive dyskinesia, its neurobiological determinants, and the conflicts of paradigms. Int. Rev. Neurobiol. 31:1989;297-353.
44. Waddington J. L. Spontaneous orofacial movements induced in rodents by very long-term neuroleptic drug administration: phenomenology, pathophysiology and putative relationship to tardive dyskinesia. Psychopharmacology. 101:1990;431-447.
45. Waddington J. L., Cross A. J., Gamble S. J., Bourne R. C. Spontaneous orofacial dyskinesia and dopaminergic function in rats after 6 months of neuroleptic treatment. Science. 220:1983;530-532.
46. Yamamoto B. K., Cooperman M. A. Differential effects of chronic antipsychotic drug treatment on extracellular glutamate and dopamine concentrations. J. Neurosci. 14:1994;4159-4166.